Interleukin 10 extends the effectiveness of standard therapy during late sepsis with serum interleukin 6 levels predicting outcome
- PMID: 15897804
Interleukin 10 extends the effectiveness of standard therapy during late sepsis with serum interleukin 6 levels predicting outcome
Abstract
Patients with septic shock often display features of T cell hyporesponsiveness and immune suppression, which, if persistent, are associated with increased mortality. In the murine cecal ligation and puncture (CLP) model of sepsis, we previously reported that early treatment with the anti-inflammatory cytokine interleukin 10 (IL-10) delays the onset of irreversible shock, defined as the time at which rescue surgery to remove the necrotic cecum is no longer effective. Because IL-10 can be immunostimulatory for T cells, we hypothesized that in the CLP model, late IL-10 treatment after removal of the infectious nidus at the onset of irreversible shock would restore T cell responsiveness and increase survival. C57BL/6J mice were subjected to lethal CLP with and without rescue surgery, concurrent with IL-10 treatment, at the onset of irreversible shock. Survival and serum IL-6 levels were measured as markers of the response to treatment. Ten hours after intervention, all groups exhibited T cell hyporesponsiveness marked by impaired interferon (IFN)-gamma production by Con A-stimulated splenocytes. IL-6 levels at 10 h were related to outcome independent of treatment. By 25 h after intervention, only the dual treatment group of cecal removal and IL-10 exhibited T cell responsiveness that was similar to pre-CLP levels (P = 0.26) and had a 7-day survival of 90% (P < or = 0.002 compared with all other groups). Thus, even in the advanced stages of septic shock when standard therapies fail, treatment with IL-10 extends the therapeutic window. For an individual mouse, the efficacy of such treatment may be predicted by an early postintervention IL-6 level.
Similar articles
-
IL-4-induced activation of the Stat6 pathway contributes to the suppression of cell-mediated immunity and death in sepsis.Surgery. 2000 Aug;128(2):133-8. doi: 10.1067/msy.2000.107282. Surgery. 2000. PMID: 10922982
-
Splenic immune suppression in sepsis: A role for IL-10-induced changes in P38 MAPK signaling.J Surg Res. 1999 May 1;83(1):36-43. doi: 10.1006/jsre.1998.5556. J Surg Res. 1999. PMID: 10210640
-
Mice depleted of alphabeta but not gammadelta T cells are resistant to mortality caused by cecal ligation and puncture.Shock. 2007 May;27(5):507-19. doi: 10.1097/SHK.0b013e31802b5d9f. Shock. 2007. PMID: 17438456
-
Interleukin-10: a complex role in the pathogenesis of sepsis syndromes and its potential as an anti-inflammatory drug.Crit Care Med. 2002 Jan;30(1 Suppl):S58-63. Crit Care Med. 2002. PMID: 11782562 Review.
-
Immunosuppressive and anti-inflammatory properties of interleukin 10.Ann Med. 1995 Oct;27(5):537-41. doi: 10.3109/07853899509002465. Ann Med. 1995. PMID: 8541028 Review.
Cited by
-
Comparison of the susceptibilities of C57BL/6 and A/J mouse strains to Streptococcus suis serotype 2 infection.Infect Immun. 2008 Sep;76(9):3901-10. doi: 10.1128/IAI.00350-08. Epub 2008 Jun 23. Infect Immun. 2008. PMID: 18573893 Free PMC article.
-
Biological agents targeting beyond TNF-alpha.Indian J Crit Care Med. 2008 Oct;12(4):181-9. doi: 10.4103/0972-5229.45079. Indian J Crit Care Med. 2008. PMID: 19742267 Free PMC article.
-
Neutrophil extracellular traps promote metastasis in gastric cancer patients with postoperative abdominal infectious complications.Nat Commun. 2022 Feb 23;13(1):1017. doi: 10.1038/s41467-022-28492-5. Nat Commun. 2022. PMID: 35197446 Free PMC article.
-
Cell type-specific regulation of IL-10 expression in inflammation and disease.Immunol Res. 2010 Jul;47(1-3):185-206. doi: 10.1007/s12026-009-8150-5. Immunol Res. 2010. PMID: 20087682 Free PMC article. Review.
-
Blocking P2X7 receptor with AZ 10606120 exacerbates vascular hyperpermeability and inflammation in murine polymicrobial sepsis.Physiol Rep. 2022 Jun;10(11):e15290. doi: 10.14814/phy2.15290. Physiol Rep. 2022. PMID: 35668576 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous